Table 1.

Overview of key pharmacological properties of secukinumab [8]

Pharmacodynamic properties
Mechanism of action	Fully human monoclonal antibody of IgG1/κ isotype; binds selectively to IL-17A and inhibits its interaction with the IL-17 receptor; inhibits the release of proinflammatory cytokines and chemokines
In pts with AS (proof-of-concept study)	↓ Levels of CRP, S100A8 and S100A9 (inflammatory biomarkers)
	↓ Signs and symptoms of AS (assessed by ASAS20) at week 6, sustained at week 28 and through 2 years
	↓ Inflammation (assessed by MRI)
	Significant correlation between clinical response (assessed by ASAS40) and genetic polymorphisms in rs30187 (a non-synonymous single-nucleotide polymorphism of ERAP1)
Pharmacokinetic properties
	Pharmacokinetic properties of SEC in pts with AS are similar to those in pts with plaque psoriasis
	First-order absorption and linear pharmacokinetics; Cmax attained ≈ 6 days after dosing; estimated bioavailability 79%; low total volume of distribution
	Most elimination via intracellular catabolism (following endocytosis); clearance 0.16 L/day; estimated terminal half-life 25.7 days; unlikely to be excreted in urine or secreted into bile
Special populationsa	Hepatic or renal impairment is not expected to influence SEC metabolism or secretion
	Age, sex and race do not affect SEC clearance
	No dosage adjustment required in pts aged ≥ 65 years
Drug interactionsa	No drug interaction studies have been performed
	The formation of CYP enzymes can be altered by ↑ levels of certain cytokines during chronic inflammation
	No interaction when SEC is coadministered with methotrexate ± corticosteroids in pts with AS or PsA

↓ decreased, ↑ increased, AS ankylosing spondylitis, ASAS20/40 improvement of ≥ 20/≥ 40% in Assessment of SpondyloArthritis international Society score, C_max maximum plasma concentration, CRP C-reactive protein, Ig immunoglobulin, IL interleukin, PsA psoriatic arthritis, pts patients, SEC secukinumab

^aConsult local prescribing information for detailed recommendations